

Understanding the Pharmaceutical Supply Chain: What is Driving Up the Cost of Drugs?

Monday, October 31, 2016

10:00 a.m. – 1:00 p.m.

State Capitol, Room 4202

Speaker Biographies

Stephen W. Schondelmeyer, PharmD, Ph.D.

Professor and Head, Department of Pharmaceutical Care & Health Systems, University of Minnesota

Dr. Schondelmeyer is a professor of Pharmaceutical Economics in the College of Pharmacy at the University of Minnesota where he holds the Century Mortar Club Endowed Chair in Pharmaceutical Management & Economics. Dr. Schondelmeyer is the Director of the PRIME Institute, which focuses on pharmaceutical research related to management and economics. He also serves as Head of the Department of Pharmaceutical Care & Health Systems.

Dr. Schondelmeyer has conducted policy analysis in many areas such as reimbursement of prescription drugs under Medicaid, Medicare, managed care and other third party programs. He was appointed to the Prescription Drug Payment Review Commission, which served in an oversight and advisory capacity to Congress for the now repealed Medicare Catastrophic Coverage Act of 1988 outpatient drug program. He has conducted research projects for a variety of sponsors including: the Centers for Medicare & Medicaid Services, the U.S. Government Accountability Office, the Congressional Office of Technology Assessment, the U.S. Senate Special Committee on Aging, the Food and Drug Administration, the pharmaceutical industry, and pharmacy associations.

Jeffrey S. Hoch, Ph.D.

Professor in the Department of Public Health Sciences University of California at Davis; Associate Director of the Center for Healthcare Research and Policy, University of California at Davis

Professor Hoch teaches courses in health economics and cost-effectiveness analysis and is involved in research projects involving methods for studying and improving value in healthcare.

After receiving a Ph.D. in health economics from the Johns Hopkins School of Public Health, Professor Hoch spent ten years running academic consulting organizations specializing in health economics research, education and consulting. He has written more than 140 peer-reviewed articles and has made more than 200 invited presentations in 15 countries.

Dr. Ramón Castellblanch

Professor, Health Education, San Francisco State University; Visiting Scholar, Institute for Research on Labor & Employment, University of California, Berkeley

Dr. Castellblanch is President of Quality Healthcare Concepts, which produces CME and CE courses related to research-based treatment of chronic pain. He represented the Senate Rules Committee on the California Board of Pharmacy from 2009 to 2016.

Gregg Jones, R.Ph.

Compliance Senior Manager, National Association of Boards of Pharmacy

Mr. Jones has been involved in the regulation and accreditation of drugs for over 30 years, beginning with the cases leading to the enactment of the 1987 Prescription Drug Marketing Act, through the current implementation of the Drug Supply Chain Security Act.

He served 26 years with Florida's Department of Health investigating counterfeit and diversion cases resulting in Florida changing its change pedigree laws.

Virginia Herold

Executive Officer, California State Board of Pharmacy

Ms. Herold has held her position with the Board of Pharmacy since July 2006. The Board regulates over 140,000 individuals and businesses that compound, dispense, ship or store prescription drugs for or to patients and practitioners in California. Consumer protection is the board's mandate. The California board is the nation's largest state board of pharmacy, and is looked up to for its innovative efforts and leadership to protect patients. Ms. Herold holds MS and BS degrees from the University of California.

Joshua J. Ofman, MD, MSHS

Senior Vice President of Global Value Access & Policy, Amgen

Dr. Ofman is responsible for directing Amgen activities related to ensuring that Amgen products have a compelling value proposition and obtain market access from payers in each market, worldwide. These activities include global pricing, market access planning, global health economics, international government affairs, and health policy.

Dr. Ofman completed his undergraduate degree in the history and philosophy of science at the University of California, Berkeley before completing his medical education at UC Irvine School of Medicine. He then completed his internship and residency in internal medicine at UCLA Medical Center. Following his residency, Dr. Ofman completed a two-year VA/UCLA/RAND fellowship in health services research, during which time he received his Masters of Science in Health Services degree from the UCLA School of Public Health. Dr. Ofman also completed a fellowship in gastroenterology at the UCLA integrated training program in digestive diseases. His research interests include health economics and technology assessment, program evaluation and health policy analysis, and he is widely published in these disciplines.

Elizabeth A. Gallenagh, Esq.

Senior Vice President, Government Affairs and General Counsel, Healthcare Distribution Alliance

Ms. Gallenagh is responsible for overseeing federal and state advocacy on behalf of the Healthcare Distribution Alliance (HDA) and its distributor members and is the organization's chief in-house attorney. Additionally, she serves as HDA's primary expert on prescription drug traceability, distributor licensure and tax issues.

Since joining HDA in 2003, Ms. Gallenagh led the Association's industry-wide efforts to replace a 50-state patchwork of pedigree laws with one national traceability solution, which became a reality through the enactment of Title II of the Drug Quality and Security Act in November 2013. In 2014, she was honored by the industry with the Distribution Management Award for Industry Leadership, which honors an individual who has exhibited the highest standards of honesty and integrity, working to enhance industry relations and knowledge, as well as supply chain efficiency and security.

Ms. Gallenagh holds a JD from the George Mason University School of Law and a BA from The George Washington University.

Elizabeth (Betsy) Imholz

Special Projects Director, Consumers Union

Ms. Imholz is an attorney and recognized expert on health policy and consumer protection. Prior to her work at Consumers Union, Ms. Imholz was the Consumer Law Coordinator of Legal Services for New York City where she started her legal career as a staff attorney in 1980. From 1991 through 1997 she was Director of the Higher Education and Training Access Project, a nonprofit advocacy and public policy project on student financial aid and vocational training. She began her focus on health policy for Consumers Union in 1997, and served on the founding Advisory Committee to the California Department of Managed Health Care (DMHC) from 2001 to 2006. She currently serves on Advisory Committees to the state Health Benefits Exchange Covered California, the UCLA California Health Information Survey, and DMHC's Fiscal Solvency Board; she is on the Board of Health Access California, and on the Executive Committee for the California consumer coalition for health insurance reform, "It's Our Healthcare."

Ms. Imholz is a Phi Beta Kappa, Magna Cum Laude graduate of Columbia University. She received her law degree in 1980 from Rutgers University in Newark, New Jersey where she was recipient of the University's G.A. Moore Prize for distinguished work in equal employment opportunity law and Articles Editor for the Women's Rights Law Reporter.